Navigation Links
GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
Date:3/15/2013

GAITHERSBURG, Md., March 15, 2013 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) will report financial results for the fourth quarter and year ended December 31, 2012 on Friday, March 22, 2013, before the U.S. financial markets open. The announcement will be followed by a webcast and conference call at 10:00 a.m. EDT to discuss the company's fourth quarter and 2012 financial results and 2013 business outlook.

To listen to the live conference call, please dial 877-558-0567 (U.S. or Canada) or 706-643-4980 (international) and use the following Conference ID: 17801867. An audio replay of the conference call will be available starting at 1:00 p.m. EDT on March 22, 2013 through March 29, 2013. To listen to the audio replay, dial 855-859-2056 or 404-537-3406 and use Conference Replay ID: 17801867.

To access the webcast or the replay, go to www.genvec.com, click on "Investors and Media," and click on "Events and Presentations."

About GenVec
GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Retail Investor and Media Contact:

GenVec, Inc.

Douglas J. Swirsky

(240) 632-5510

dswirsky@genvec.com

Institutional Investor Contact:

S.A. Noonan Communications

Susan A. Noonan

(212) 966-3650

susan@sanoonan.com


'/>"/>
SOURCE GenVec, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec to Present at 25th Annual ROTH Conference
2. GenVec Reports Third Quarter 2012 Financial Results
3. GenVec Reports Second Quarter 2012 Financial Results
4. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
5. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
6. GenVec Reports Inducement Award
7. GenVec Appoints Cynthia Collins as President and CEO
8. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
9. GeneTex to Release New Antibodies for the Study of DNA Repair in Zebrafish
10. Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
11. Ranbaxy to Market Desvenlafaxine Base Extended Release Tablets in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... 2017 , ... As President Trump challenges the status quo ... administration could impact the employee benefits industry. James Slotnick, AVP, Government Relations, for ... make it through Congress. His discussion will focus on the current state of ...
(Date:4/25/2017)... NV (PRWEB) , ... April 25, 2017 , ... ... now choose a modern procedure that achieves results in a fraction of the ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment ...
(Date:4/25/2017)... ... ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – from medical ... heartened by the industry’s current surge. But another thing that unifies them is a ... last they can simply, safely and effectively end their aroma anguish thanks to a ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South Florida ... report in the May issue of Consumer Reports focused on heart health. , ... achieved during and after coronary bypass and aortic valve replacement procedures. , Consumer ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG CNS Healthcare Solutions ... (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national conference. , BYOD ... devices with a pre-programmed tablet in a remarkably easy-to-use kit for patients. “BYOD ...
Breaking Medicine News(10 mins):